MDAI

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on: 
Monday, April 1, 2024
Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points: 
  • DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
  • Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
  • Mr. Sparks will be responsible for both domestic and international product commercialization.
  • “We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, March 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.

Spectral AI Secures Access to $12.5 Million of New Equity Capital

Retrieved on: 
Wednesday, March 20, 2024
Burn, MDAI, Research, Ulcer, Artificial intelligence, Sale, Government agency, Spectral, Capital punishment

DALLAS, March 20, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has entered into a fixed price prepaid advance and standby equity purchase agreement (“SEPA”) with a long-only investor. Total capacity under the SEPA is $30.0 million, consisting of a prepaid advance of $12.5 million, $5.0 million of which was funded today with a fixed conversion price of $3.16. Any additional draws above the prepaid advances are at the sole discretion of the Company.

Key Points: 
  • Total capacity under the SEPA is $30.0 million, consisting of a prepaid advance of $12.5 million, $5.0 million of which was funded today with a fixed conversion price of $3.16.
  • Any additional draws above the prepaid advances are at the sole discretion of the Company.
  • “We are pleased to announce this equity funding as we pivot to commercialization while continuing our research and development activities,” said Peter M. Carlson, CEO of Spectral AI.
  • “Together with our non-dilutive funding from various U.S. Government agencies, this new equity-linked instrument supports our strategic imperatives.

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

Retrieved on: 
Tuesday, March 19, 2024
MDAI, Patent, Intellectual property, Artificial intelligence, IP, AI, Spectral, Ecosystem, Medical device

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).

Key Points: 
  • DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).
  • Spectral IP will focus on advancing intellectual property (IP) in the broader AI ecosystem through acquisitions, strategic partnerships and collaborations with AI technology providers, healthcare institutions, and research organizations to accelerate innovation and expand market reach.
  • Wensheng Fan, Spectral AI’s Chief Innovation Strategist, said, “Medical Device companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in AI.
  • The integration of Artificial Intelligence is increasing in the medical device industry, but still lags other industries in its adoption.

Spectral AI Schedules 2023 Fourth Quarter and Full Year Financial Results and Conference Call

Retrieved on: 
Wednesday, March 13, 2024
MDAI, Artificial intelligence

DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market.

Key Points: 
  • DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market.
  • The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
  • Investors interested in participating in the live call can dial:

Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

Retrieved on: 
Tuesday, March 12, 2024
Government, DHA, Health, MDAI, Patient, Artificial intelligence, Spectral, Miniaturization, Defense, State, Medical device

The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness.

Key Points: 
  • The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness.
  • These optimizations will, in turn, increase the device’s potential for a portable, handheld version for home health care and related invaluable assistance to medical professionals in many settings.
  • “Spectral AI is proud to partner with DHA and the USAMMDA on this crucial initiative.
  • This award further validates Spectral AI’s technology and the importance of a battlefield burn solution we are focusing on,” stated Pete Carlson, CEO of Spectral AI.

Spectral AI Announces Intellectual Property Subsidiary to Focus on the Broader AI Healthcare Ecosystem

Retrieved on: 
Thursday, March 7, 2024
Executive Committee, Intellectual property, Ecosystem, Health, MDAI, Artificial intelligence, Spectral

DALLAS, March 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare.

Key Points: 
  • DALLAS, March 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare.
  • “After conducting a comprehensive review of our IP portfolio, we are confident that Spectral AI has effectively safeguarded its current and anticipated future product offerings through a combination of patents and trade secrets.
  • During this review, we identified additional opportunities for the Company to enhance its position and add value for its shareholders by developing or acquiring IP applicable to the broader AI ecosystem—specifically within healthcare,” said Pete Carlson, Chief Executive Officer.
  • He will collaborate closely with the Company on this initiative.”
    Spectral AI remains committed to advancing AI-driven solutions in healthcare, including opportunities and strategic developments fostered by its new subsidiary.

Spectral AI Appoints Peter M. Carlson as CEO

Retrieved on: 
Thursday, February 29, 2024
Momentum, CFO, UKCA, Burn, Artificial intelligence, MiMedx, Spectral, FDA, Growth, MDAI, Brings, Highlight, Senior advisor, Classification, Burns, DFU, Corporation

DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its Board of Directors (the “Board”) has appointed Peter M. Carlson, Spectral AI’s current Chief Financial Officer, as Chief Executive Officer and a member of the Board. He succeeds Wensheng Fan, who, after 14 years with Spectral AI, including nearly four as CEO, is transitioning to Chief Innovation Strategist and Senior Advisor to the CEO. Vincent S. Capone, Spectral AI’s General Counsel and Corporate Secretary, will assume the additional role of Chief Financial Officer.

Key Points: 
  • He succeeds Wensheng Fan, who, after 14 years with Spectral AI, including nearly four as CEO, is transitioning to Chief Innovation Strategist and Senior Advisor to the CEO.
  • Vincent S. Capone, Spectral AI’s General Counsel and Corporate Secretary, will assume the additional role of Chief Financial Officer.
  • He joined Spectral AI as CFO in January 2024 following the Company’s debut on the NASDAQ Global Market.
  • “In his short time here, Pete has already distinguished himself as a skilled and experienced leader and a tremendous asset to Spectral AI.

Spectral AI to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 28, 2024
Interest, MDAI, Artificial intelligence, Spectral

DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to participate in the following investor conferences:

Key Points: 
  • DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to participate in the following investor conferences:
    Management will be hosting 1x1 meetings during these conferences.
  • Interested parties may access live and archived webcasts of these events by visiting the Investors section of Spectral AI’s website at https://investors.spectral-ai.com/news-events/events .

Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

Retrieved on: 
Thursday, February 22, 2024
UKCA, Algorithm, Burn, Artificial intelligence, Spectral, MDAI, Sale, Surgeon, Government, Observation, Ageing, Nursing

"I am delighted to announce this achievement in our Company’s evolution.

Key Points: 
  • "I am delighted to announce this achievement in our Company’s evolution.
  • “In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization.”   Revenue from commercialization in the UK in 2024 represents an addition to the $28 million revenue guidance previously communicated by the Company.
  • “This protracted decision process burdens the patient as well as the healthcare system with unnecessary hospitalization time.
  • The Company aims to extend its technology to benefit pediatric populations and is continuing to initiate case studies and case series with surgeons at leading burn centers.